The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer | MicrobiomeTrials← Back to trialsNCT07565987
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-12-19Est. Completion: 2029-12-18
Enrollment target: 20 participants Locations- Nci, Aiims-Jhajjar, Jhajjar, Haryana, India
Other microbiome trials you might be interested in
Non-Small Cell Lung Cancer (NSCLC)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who rece…
Santa Barbara, United StatesEst. completion Jun 30, 2027
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma
2L+ Cervical Cancer
Neoadjuvant Melanoma
Neoadjuvant Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Post Anti-PD-(L)1 Small Cell Lung Cancer
Third Line or Later (3L+) HER2+ Breast Cancer
Second or Third Line (2L/3L) Cervical Cancer
Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United StatesEst. completion Aug 2027
Ovarian CancerNon-small Cell Lung Cancer
The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokineti…
Birmingham, United StatesEst. completion Dec 2027